- Home
- BOKF vs JAZZ Comparison
BOKF vs JAZZ Comparison
Compare BOKF & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOKF
- JAZZ
- Stock Information
- Founded
- BOKF 1910
- JAZZ 2003
- Country
- BOKF United States
- JAZZ Ireland
- Employees
- BOKF N/A
- JAZZ N/A
- Industry
- BOKF Major Banks
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- BOKF Finance
- JAZZ Health Care
- Exchange
- BOKF Nasdaq
- JAZZ Nasdaq
- Market Cap
- BOKF 6.9B
- JAZZ 7.3B
- IPO Year
- BOKF N/A
- JAZZ 2007
- Fundamental
- Price
- BOKF $114.26
- JAZZ $121.43
- Analyst Decision
- BOKF Buy
- JAZZ Buy
- Analyst Count
- BOKF 12
- JAZZ 14
- Target Price
- BOKF $113.45
- JAZZ $173.93
- AVG Volume (30 Days)
- BOKF 133.6K
- JAZZ 567.6K
- Earning Date
- BOKF 01-17-2025
- JAZZ 02-26-2025
- Dividend Yield
- BOKF 1.99%
- JAZZ N/A
- EPS Growth
- BOKF 1.50
- JAZZ 458.10
- EPS
- BOKF 8.14
- JAZZ 7.04
- Revenue
- BOKF $2,032,399,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- BOKF N/A
- JAZZ $7.51
- Revenue Next Year
- BOKF $5.55
- JAZZ $6.84
- P/E Ratio
- BOKF $14.04
- JAZZ $17.18
- Revenue Growth
- BOKF 0.81
- JAZZ 5.23
- 52 Week Low
- BOKF $77.86
- JAZZ $99.06
- 52 Week High
- BOKF $121.58
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- BOKF 59.67
- JAZZ 47.48
- Support Level
- BOKF $103.63
- JAZZ $118.72
- Resistance Level
- BOKF $113.50
- JAZZ $124.66
- Average True Range (ATR)
- BOKF 2.36
- JAZZ 2.79
- MACD
- BOKF 0.90
- JAZZ -0.24
- Stochastic Oscillator
- BOKF 83.97
- JAZZ 39.45
About BOKF BOK Financial Corporation
BOK Financial Corp is the largest financial institution in Oklahoma and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.